Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib with carboplatin/etoposide/atezolizumab in extensive-stage SCLC
NCT03041311Phase 2Completed
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Jun 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Trilaciclib + E/P/A with Placebo + E/P/A (2 arms). Primary endpoints: Duration of Severe Neutropenia in Cycle 1 and Occurrence of Severe Neutropenia. Started Jun 2017; status: completed.
02
Drugs
trilaciclib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03041311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03041311.